Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | COMT | P21964 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | METAP2 | P50579 | 1/20 | 0.47 |
| ▸ | METAP1 | P53582 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | GMNN | O75496 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12899533 | 0.86 | PARP1 (0.51) | PARP1HDAC6ALDH1A1LMNAMMP2 | |
| SCHEMBL3711541 | 0.84 | KDM4E (0.59) | PARP1HDAC6ALDH1A1LMNAMMP2 | |
| SCHEMBL19036261 | 0.84 | HDAC6 (0.50) | PARP1HDAC6ALDH1A1LMNAMMP2 | |
| SCHEMBL30553881 | 0.84 | KDM4E (0.59) | PARP1HDAC6ALDH1A1LMNAMMP2 | |
| SCHEMBL9268906 | 0.83 | HDAC6 (0.49) | PARP1HDAC6ALDH1A1LMNAMMP2 | |
| SCHEMBL6189901 | 0.83 | PARP1 (0.49) | PARP1HDAC6ALDH1A1LMNAMMP2 | |
| SCHEMBL1285339 | 0.82 | PARP1 (0.53) | PARP1HDAC6ALDH1A1LMNAMMP2 | |
| SCHEMBL29456254 | 0.79 | MAPK8 (0.45) | PARP1HDAC6ALDH1A1LMNAADRA1A | |
| SCHEMBL6902980 | 0.79 | MAPK8 (0.45) | PARP1HDAC6ALDH1A1LMNAADRA1A | |
| SCHEMBL24822355 | 0.79 | HDAC6 (0.49) | PARP1HDAC6ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110423217-B | Preparation method of conjugated eneyne compound | 大连理工大学 | 2022-04-12 | — | — | CN | claimed |
| CN-110423217-A | A kind of preparation method of conjugated enynes compound | UNIV DALIAN TECH | 2019-11-08 | — | — | CN | claimed |
| CN-107522658-B | Sour cyanines probe in a kind of symmetrical side in 1,3 based on amide groups quinoline and its preparation method and application | 常州大学 | 2019-06-04 | — | — | CN | claimed |
| CN-107522658-A | A kind of 1,3 symmetrical sour cyanines probes in side based on amide groups quinoline and its preparation method and application | 常州大学 | 2017-12-29 | — | — | CN | claimed |
| CN-104592983-B | Fluorescent probes based on pyrene, and preparation method and application thereof | 渤海大学 | 2017-03-22 | — | — | CN | claimed |
| CN-105038769-A | Fluorescent probe based on 8-aminoquinoline derivative and synthetic method and application thereof | UNIV BOHAI | 2015-11-11 | — | — | CN | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20220081427-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| CN-110423217-A | A kind of preparation method of conjugated enynes compound | UNIV DALIAN TECH | 2019-11-08 | — | — | CN | disclosed |
| CN-107522658-B | Sour cyanines probe in a kind of symmetrical side in 1,3 based on amide groups quinoline and its preparation method and application | 常州大学 | 2019-06-04 | — | — | CN | disclosed |
| CN-108250141-A | Methyl-P-tyrosine modifies N-（8- quinolyls）Acetamide compound, synthetic method and application | 华南师范大学 | 2018-07-06 | — | — | CN | disclosed |
| CN-108250141-A | Methyl-P-tyrosine modifies N-（8- quinolyls）Acetamide compound, synthetic method and application | 华南师范大学 | 2018-07-06 | — | — | CN | disclosed |
| CN-105038769-A | Fluorescent probe based on 8-aminoquinoline derivative and synthetic method and application thereof | UNIV BOHAI | 2015-11-11 | — | — | CN | disclosed |
| CN-100412062-C | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED INC (CA) | 2008-08-20 | — | — | CN | disclosed |
| CN-1608052-A | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED INC (CA) | 2005-04-20 | — | — | CN | disclosed |
| US-5405843-A | Anticancer drug potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-04-11 | — | — | US | disclosed |
| EP-0363212-B1 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS (JP) | 1995-01-04 | — | — | EP | disclosed |
| US-5204348-A | Quinoline derivatives | MITSUI TOATSU CHEMICALS INC. (JP) | 1993-04-20 | — | — | US | disclosed |
| US-5112817-A | Anticancer Drug Potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1992-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081427-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | PARP1 1492/4885HDAC6 420/4885ALDH1A1 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.